Cancer Flashcards

1
Q

examples of post-mitotic cells

A

*significance: tumors not associated with these cell types

skeletal muscle, cardiac muscle, mature neurons

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Highest incidence and highest mortality

A
  1. prostate/breast
  2. lung
  3. colon/rectum

1 and 2 flipped for death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Expt to prove tumor cells are monoclonal

A
  • random X inactivation in females, tumors express one or other allele of a distinguishable gene product
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

cancer cell heterogeneity

A

At different stages in cancer progression, cells face different selective pressures that promote the survival of cells that have acquired a particular variation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

CSC and therapy hypotheses

A
  1. Hierarchic CSC model - conventional therapy: CSCs are more resistant than differentiated cells to therapy and persist, quick relapse
  2. Hierarchic CSC model - CSC-specific therapy: in theory, CSC ablation should lead to decline of malignancy
  3. dynamic CSC - CSC-specific therapy: differentiated cells can reacquire CSC features through signaling from stromal cells and relapse will ensue
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Warburg Effect

A

Even in presence of O2, cancer cells have elevated levels of glycolysis. Can take advantage of this by giving tagged glucose to see on PET scan

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

cyclins and CDKs of G1 to S transition

A

cyclin D/CDK 4 and 6

cyclin E/CDK 2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

cyclins and CDKs of S phase

A

cyclin A/CDK 2 and 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

cyclin and CDK of G2 to M

A

cyclin B/CDK 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

inhibitors of cyclin D/CDK 4 and 6

A

p15, p16, p18, p19

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

inhibitors of all CDKs

A

p21, p27, p57

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is most severe histological feature?

A

anaplasia, lack resemblance to normal counterpart. not good sign!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

pleomorphism

A

variation in cell size and shape

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

clonal selection and tumor progression

A
  • clonal selection: initial mutation that confers growth advantage to cell and its progeny
  • tumor progression: additional mutations that occur that give further growth advantage and account for malignant characteristics of a tumor
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

grading vs staging

A

just looking at tumor vs. looking at tumors invasiveness (use for prognosis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

lymphatic spread vs hematogenous spread

A
  • lymphatic is common for carcinomas

- hematologic is common for sarcomas: metastasis to liver, lung, bone, and brain are common

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

IHC

A
used to determine what tissue type tumor came from, or to see if anaplasia is present 
keratin: epithelial
vimentin: mesenchymal
LCA: lymphoid
S100: neural and melanocytic
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

flow cytometry

A

used to classify lymphoma/leukemia by surface antigens
- T/B cell, myeloid, degree of differentiation

  • also used for apoptosis assay
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

FISH for cancer

A

detects loss of tumor suppressors, amplification of oncogenes, and translocations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

PCR for cancer

A

assess for specific mutations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

RT-PCR

A

RNA into cDNA

i.e. BCR-ABL fusion protein

22
Q

PSA

A

IHC

- high false positive, secreted into blood in prostate ca

23
Q

TTF1

A

IHC
thyroid transcription factor 1
- positive in many lung cancers, as well as thyroid cancer

24
Q

myogenin

A

IHC

- expressed in rhabdomyosarcoma (recapitulates early muscle)

25
Q

Ki67

A

nuclear proliferation marker
high Ki67 = low doubling time
- can sometimes be helpful

26
Q

C-Kit/CD1117

A
  • often seen in GIST (GI stromal tumor)

tyrosine protein kinase that can be mutated, cancer may be respond to Gleevac

27
Q

p53 mutation and IHC

A

seen as positive in nuclear staining, longer half life and accumulates in cell

28
Q

percentage of cancers attributable to infection in developing countries

A

26%

29
Q

percentage of cancers familial vs. sporadic

A

familial: 5-10%
sporadic: 70-80%

family cluster: 15-20%

30
Q

Characteristics of known carcinogen

A
  1. ca epidemiology studies
  2. clinical studies
  3. study of tissues/cells from exposed human
31
Q

reasonably anticipated to be carcinogen

A
  1. multiple species
  2. multiple tissue sites
  3. multiple routes of exposure
  4. structurally related to known carcinogen
  5. similar mechanism
32
Q

Oncogenic viruses

A
  1. HTLV: leukemia/lympomas
  2. HPV: cervical
  3. EBV: Burkitt’s lympoma
  4. HCV: liver
33
Q

HPV mechanism

A
  • E6 degrades p53

- E7 binds RB, removing its inhibitory effects on E2F –> proliferation

34
Q

H. pylori

A

only known bacterium implicated in genesis of cancer (adenocarcinomas and gastric lymphomas)

35
Q

two cytogenetic manifestations of gene amplification

A

HSR (FISH)

double minutes

36
Q

n-Myc

A

commonly found in neuroblastoma

37
Q

c-Myc

A

Burkitt’s Lymphoma

38
Q

L-Myc

A

small cell lung carcinoma

39
Q

proto-oncogene family erb B (EGFR)

A

80% squamous cell carcinoma of lung
50% glioblastoma
80-100% tumors of head and neck

40
Q

proto-oncogene family Ras

A

90% pancreas
50% colon
50% thyroid
30% lung

41
Q

proto-oncogene family Myc

A
  • L-Myc: small lung cell carcinoma
  • c-Myc: Burkitt’s lymphoma
  • n-Myc: neuroblastoma
42
Q

CML chromosomes

A

(9;22) abl kinase, bcr regulator

43
Q

Burkitt’s Lymphoma translocation

A

(8;14) myc on 8 near Ig regulator on 14

44
Q

Promyelocytic leukemia

A

t(15;17) –> treat with all trans RA to release NCOR/HDAC and allow promyelocytes to differentiate

45
Q

Myelomonocytic leukemia

A

inv(16)

46
Q

Myeloblastic leukemia

A

(8;21)

47
Q

Ewing Sarcoma

A

t(11;22)

48
Q

Meningioma

A

Monosomy 22

49
Q

Retinoblastoma

A

del(13)(q14)

50
Q

alveolar rhabdomyosarcoma

A

t(2;13)

51
Q

synovial sarcoma

A

t(X,18)